Alpha thalassemia gene analysis

Genetic

Report in 288Hrs

At Home

No Fasting Required

Details

Genetic test for deletions/mutations in alpha-globin genes.

₹22,496₹32,137

30% OFF

Alpha Thalassemia Gene Analysis - Comprehensive Medical Test Guide

Section 1: Why is it done?
- Test Purpose: Detects mutations in the HBA1 and HBA2 genes that encode alpha-globin chains, which are essential components of hemoglobin. This genetic test identifies deletions, point mutations, and other abnormalities responsible for alpha thalassemia.
- Screening for Alpha Thalassemia Carrier Status: Identifies individuals who carry one mutated alpha-globin gene (silent carriers or alpha thalassemia trait), who typically have no symptoms but may pass the condition to offspring
- Diagnosis of Alpha Thalassemia Disease: Confirms suspected cases of HbH disease (three deleted alpha-globin genes) or alpha thalassemia major (four deleted genes) in symptomatic patients presenting with hemolytic anemia
- Prenatal Diagnosis: Performed during pregnancy via amniocentesis or chorionic villus sampling (CVS) to detect alpha thalassemia in the developing fetus, particularly when both parents are known carriers
- Unexplained Microcytic Anemia: Evaluates patients with microcytic hypochromic anemia to differentiate alpha thalassemia from iron deficiency anemia or beta thalassemia trait
- Family Planning and Genetic Counseling: Assists couples of high-risk populations (Southeast Asian, Mediterranean, Middle Eastern, African descent) in understanding carrier status and reproductive risks
- Timing: Performed at any time if carrier screening is desired; during prenatal visits in high-risk pregnancies; when hemolytic anemia is clinically suspected; prior to bone marrow or stem cell transplantation consideration
Section 2: Normal Range
- Normal Result (No Mutations): Presence of intact, normally functioning HBA1 and HBA2 genes with four functional alpha-globin gene copies (two from each parent). This indicates the patient is not a carrier and has no alpha thalassemia
- Standard Notation: Results typically reported as 'No alpha-globin gene mutations detected' or '--/αα (alpha-alpha gene configuration) representing two normal alpha genes from each parent
- Interpretation of Normal Range: A normal result confirms the individual has two functional copies of each alpha-globin gene, sufficient for normal hemoglobin production and oxygen transport without risk of thalassemia-related complications
- Abnormal Results Classification:
  - Silent Carrier (One Deletion, --/αα or -α/-α): One alpha-globin gene deletion; typically asymptomatic with normal or near-normal hemoglobin levels; may show subtle decrease in MCV; found in 1-5% of certain populations
  - Alpha Thalassemia Trait (Two Deletions, -α/-α or --/--): Two deleted genes; mild microcytic hypochromic anemia with MCV typically 60-75 fL; hemoglobin slightly reduced; individuals are clinically asymptomatic but are carriers for severe forms
  - HbH Disease (Three Deletions, -α/--): Three deleted genes; moderate hemolytic anemia with MCV 60-70 fL; splenomegaly common; jaundice possible; generally compatible with life but requires monitoring
  - Alpha Thalassemia Major/Hydrops Fetalis (Four Deletions, --/--): All four alpha-globin genes deleted; severe hemolytic anemia incompatible with life; results in intrauterine death, stillbirth, or severe complications at birth; requires in utero intervention or transfusions
- Units of Measurement: Results expressed as number of deleted or mutated alpha-globin genes (0-4 out of 4 possible); specific genetic mutations identified and classified according to Southeast Asian, Mediterranean, African, or other deletion patterns
Section 3: Interpretation
- Genetic Basis of Alpha Thalassemia: The alpha-globin genes are located on chromosome 16, with individuals normally inheriting two alpha-globin genes from each parent (four total). Each deletion or mutation reduces functional alpha-globin chain production proportionally
- Common Deletion Patterns: Southeast Asian deletions (--SEA, -α3.7, -α4.2) account for ~80% of cases; Mediterranean deletions (--MED, -α4.2) account for ~15%; African and other rare deletions comprise remaining cases. Point mutations (non-deletional) are less common but increasingly recognized
- Correlation with Complete Blood Count (CBC): Three-gene deletions present with hemoglobin 7-10 g/dL, MCV 55-70 fL, and red cell count usually >5×10⁶/µL; two-gene deletions show hemoglobin 11-13 g/dL, MCV 60-75 fL; one-gene deletion may appear nearly normal
- Hemoglobin H (HbH) Testing: Patients with HbH disease (three deletions) form tetramers of beta chains (β4) visible as Heinz bodies on supravital staining. HbH comprises 4-30% of total hemoglobin; alpha-globin chains are severely deficient
- Factors Affecting Interpretation: Ethnic background influences expected deletion patterns; presence of co-inherited conditions (iron overload, splenectomy, concurrent infections) modifies clinical presentation; age influences symptom severity and compensatory mechanisms
- Alpha Globin Gene Cluster Organization: Understanding that deletions remove adjacent DNA sequences helps predict which specific genes are affected; -α3.7 deletion removes one HBA2 and part of HBA1; --SEA and --MED deletions remove both HBA1 and HBA2 genes on one chromosome
- Phenotype-Genotype Correlation: Two-gene deletions show remarkable clinical variation; homozygous -α3.7/-α3.7 deletions typically produce mild anemia, while heterozygous --/- α3.7 genotypes may present more severely. Environmental factors, fetal hemoglobin retention, and genetic modifiers influence outcomes
- Clinical Significance of Results: Silent carriers have minimal clinical impact with normal lifespan but should receive genetic counseling. Trait carriers have mild, stable anemia without symptoms. HbH disease patients experience chronic hemolysis with potential complications (gallstones, splenomegaly, bone changes). Alpha thalassemia major is incompatible with postnatal life without intervention
Section 4: Associated Organs
- Primary Organ System: Hematopoietic System
  - Bone marrow experiences marked expansion and extramedullary hematopoiesis in moderate-severe disease; ineffective erythropoiesis leads to accelerated red blood cell destruction and shortened RBC lifespan (30-60 days vs normal 120 days)
- Secondary Organ Involvement:
  - Spleen: Progressively enlarges (splenomegaly) due to increased RBC destruction and extramedullary hematopoiesis; can become massively enlarged, occupying significant abdominal space; hypersplenism develops leading to additional anemia, thrombocytopenia, and leukopenia; splenic sequestration crisis may occur
  - Liver: Hepatomegaly develops from extramedullary hematopoiesis and iron deposition; chronic hemolysis increases bilirubin processing; risk of gallstone formation (pigment stones) and cholecystitis, particularly in HbH disease; potential cirrhosis with iron overload
  - Heart: Anemia-induced high-output cardiac state with tachycardia and increased cardiac workload; iron deposition in cardiac myocytes (in transfusion-dependent patients) causes cardiomyopathy and arrhythmias; congestive heart failure may develop
  - Bones: Skeletal abnormalities develop from marrow expansion; frontal bossing, maxillary prominence, and chipmunk facies from facial bone expansion; osteoporosis and pathologic fractures from abnormal bone remodeling; vertebral compression fractures possible
  - Endocrine System: Hypogonadism and delayed puberty from iron deposition in pituitary gland and testes; diabetes mellitus from pancreatic iron infiltration; hypothyroidism possible; growth retardation in untreated severe disease
  - Central Nervous System: In utero hypoxia in alpha thalassemia major leads to severe developmental complications; postnatal hypoxia from severe anemia can cause neurologic damage; transfusional hemosiderosis affects cognition
  - Lungs: Pulmonary complications from chronic hypoxia and hemolysis; potential pulmonary hypertension from chronic anemia; increased risk of infections; thromboembolic complications
  - Kidneys: Proteinuria and glomerulonephritis from chronic hemolysis; heme-associated renal injury; potential chronic kidney disease development; ability to concentrate urine may be impaired
- Major Complications Associated with Alpha Thalassemia:
  - Intrauterine Death: Alpha thalassemia major (--/--) typically results in hydrops fetalis with polyhydramnios, hepatosplenomegaly, edema, and cardiac failure in utero
  - Hemolytic Anemia Complications: Acute hemolytic episodes, aplastic crisis (especially with parvovirus B19 infection), splenic sequestration crisis causing sudden severe anemia and shock
  - Transfusion-Related Complications: Iron overload (hemosiderosis) from multiple blood transfusions causing organ damage; alloimmunization and delayed transfusion reactions; blood-borne infections risk
  - Thrombotic Complications: Increased risk of venous and arterial thromboembolism from abnormal RBC membrane properties and activation of coagulation pathways; stroke and myocardial infarction possible
  - Infections: Increased susceptibility to bacterial infections; splenectomy-related sepsis risk; opportunistic infections from chronic disease states
Section 5: Follow-up Tests
- Initial Confirmatory and Characterization Tests:
  - Complete Blood Count (CBC) with differential: Assess hemoglobin levels, MCV, MCH, red cell indices; evaluate anemia severity; baseline and monitoring for disease progression and treatment response
  - Hemoglobin Electrophoresis or High-Performance Liquid Chromatography (HPLC): Quantify different hemoglobin types (HbA, HbH, HbF); measure percentage of abnormal hemoglobins; detect HbH in three-gene deletion cases; confirm diagnosis and assess severity
  - Peripheral Blood Smear: Identify target cells, schistocytes, and morphologic abnormalities; assess red blood cell morphology; detect Heinz bodies after supravital staining (particularly HbH disease)
  - Reticulocyte Count: Assess bone marrow response and compensatory erythropoiesis; elevated in hemolytic states; helpful for differentiating from other causes of anemia
- Genetic and Family Planning Tests:
  - Partner/Spouse Alpha-Globin Gene Analysis: Determine if partner carries alpha thalassemia mutations; assess risk of affected offspring; essential for genetic counseling and reproductive planning decisions
  - Beta-Globin Gene Analysis: Rule out concurrent beta thalassemia trait; important as alpha and beta thalassemia can co-inherit; helps clarify diagnosis when anemia phenotype is ambiguous
  - Prenatal Diagnosis Testing (if applicable): Amniocentesis or chorionic villus sampling for alpha-globin gene analysis; performed at 15-20 weeks (amniocentesis) or 10-12 weeks (CVS) for at-risk pregnancies; allows informed decision-making and early intervention planning
  - Non-invasive Prenatal Testing (NIPT): Cell-free fetal DNA testing for high-risk pregnancies; can detect alpha thalassemia major; reduces need for invasive procedures; performed at 10+ weeks gestation
- Organ Function and Complication Monitoring:
  - Iron Studies (Serum ferritin, transferrin saturation, soluble transferrin receptor): Assess iron overload status; baseline and every 3-6 months in HbH disease or transfusion-dependent patients; ferritin >1000 ng/mL suggests significant iron accumulation
  - Liver Function Tests (Bilirubin, AST, ALT, albumin): Assess bilirubin elevations from hemolysis; evaluate hepatic synthetic function; baseline and annually; elevated bilirubin indicates active hemolysis
  - Lactate Dehydrogenase (LDH) and Haptoglobin: Markers of hemolysis; elevated LDH and low haptoglobin confirm ongoing hemolytic anemia; monitored during crisis episodes and disease monitoring
  - Renal Function Tests (Creatinine, BUN, urinalysis): Screen for renal complications from hemolysis; baseline and annually; detect proteinuria indicating glomerulonephritis
  - Thyroid Function Tests (TSH, Free T4): Screen for hypothyroidism from iron deposition; baseline and every 1-2 years in HbH disease patients
  - Cardiac Imaging (Echocardiography): Baseline and every 2-3 years; assess cardiac function in HbH disease; evaluate for cardiomyopathy and chamber dilation; screen for pulmonary hypertension
  - Cardiac Iron Quantification (T2* MRI): For transfusion-dependent patients; assess myocardial iron deposition; guide chelation therapy intensity; baseline and annually if transfused
  - Hepatic Iron Quantification (Liver T2* MRI or SQUID): Assess liver iron deposition for all transfusion-dependent patients; baseline and annually; guides chelation therapy decisions
  - Abdominal Ultrasound: Screen for hepatosplenomegaly progression, gallstones, and cirrhosis; baseline and every 1-2 years if abnormalities detected
- Transfusion-Related Monitoring:
  - Blood Typing and Antibody Screening: Before each transfusion; screen for alloimmunization; identify compatible red cell units; baseline and with each transfusion in frequently transfused patients
  - Infectious Disease Screening: HIV, hepatitis B and C, syphilis before transfusion and periodically; baseline and annually; screen for parvovirus B19 during aplastic crisis
- Specialist Consultations and Monitoring Intervals:
  - Genetic Counseling: At diagnosis and before reproductive decisions; discuss inheritance patterns, recurrence risks, and management options; resources for patient education and support
  - Hematology Follow-up: Every 3-6 months for asymptomatic carriers; every 1-3 months for HbH disease; more frequently if unstable; assess anemia trends and complications
  - Pediatric Assessment: In diagnosed children, developmental milestones, growth parameters, pubertal development; assess for manifestations of bone marrow expansion (facial changes, skeletal deformities)
Section 6: Fasting Required?
- Fasting Status: NO
- Explanation: Alpha thalassemia gene analysis is a genetic test performed on DNA extracted from blood or other tissue samples. Unlike tests measuring glucose, lipids, or other metabolites, genetic testing results are not affected by food or beverage intake. Fasting is not required prior to sample collection
- Sample Collection Requirements:
  - Blood Draw: 3-5 mL of peripheral venous blood collected in EDTA (lavender-top) tube; timing irrelevant to meals; can be collected at any time of day
  - Prenatal Samples: Amniotic fluid (10-15 mL) collected via amniocentesis or chorionic villus sample (CVS) collected as appropriate for gestational age; no fasting required
  - Alternative Samples: Buccal swabs or saliva can be used for non-invasive DNA collection; cheek cells provide adequate DNA for testing
- Medications and Supplements:
  - No Medication Restrictions: Genetic testing is not affected by any medications, supplements, or herbal preparations. Continue all regular medications as prescribed; inform laboratory of medications only if tracking for clinical correlation purposes
  - Iron Supplements: Continue iron supplementation if taking for anemia management; does not interfere with genetic test results; blood draw can be performed at any time relative to iron supplement dosing
  - Chelation Therapy: Patients on iron chelation agents (deferasirox, deferiprone, deferoxamine) should continue normal dosing; chelation does not affect DNA integrity or genetic test accuracy
- Additional Patient Preparation:
  - Informed Consent: Review test purpose, implications, and potential results with healthcare provider; understand genetic counseling availability; discuss privacy and confidentiality of genetic information
  - Ethnic Background Information: Provide ethnicity or ancestry information to laboratory if known; helps guide analysis for expected deletion patterns (Southeast Asian, Mediterranean, African, etc.) and enables more targeted interpretation
  - Clinical History Documentation: Provide complete medical history including anemia symptoms, family history of thalassemia, CBC results, hemoglobin electrophoresis if available; helps pathologist correlate genetic findings with clinical presentation
  - Timing Considerations: Test can be performed any time without special timing; no advantage to testing at specific times of day or week; arrange test scheduling at convenient times; results typically available within 1-4 weeks depending on laboratory and testing method used
  - Psychological Preparation: Understand that genetic test results have implications for family members; consider genetic counseling before and after testing; discuss impact on reproductive choices and life planning with healthcare provider or genetic counselor
  - Post-Test Counseling: Schedule follow-up appointment to discuss results; review implications with healthcare provider; determine need for family member testing; establish ongoing monitoring plan if abnormalities identified

How our test process works!